{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:31:50Z","timestamp":1762540310699},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,3,20]],"date-time":"2002-03-20T00:00:00Z","timestamp":1016582400000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Drug treatment of idiopathic Parkinson's disease (IPD) is a difficult task, and comorbidity and comedication add to its complexity. Since in IPD there is little information about drug use, this study investigated drug prescribing and indications in IPD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From June 1997 to April 1998, a cross\u2010sectional survey of IPD outpatients was performed and demographic and clinical data and information about drug treatments was collected and analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the 130 IPD patients included in the study, anti\u2010Parkinson drug (APD) prescriptions increased with disease duration and severity. Levodopa was most frequently used, followed by dopamine agonists and anticholinergic agents. Levodopa with other APDs was given to older patients with later IPD onset. Prescriptions of drugs for other indications (non\u2010APDs) were given to 80.8% of the patients and their number increased with patient age. Non\u2010APD prescriptions concerned mainly the circulatory system, mental disorders, the musculo\u2010skeletal system and the digestive system. Prescriptions for indications corresponding to secondary symptoms that often complicate IPD increased with patient age and also with IPD duration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In IPD patients, disease duration and severity and patient age seem to be major determinants of drug use. Indications for drug prescription suggest that main comorbidity includes neuropsychiatric, circulatory, musculo\u2010skeletal and digestive disorders. Analysis of prescribing patterns in IPD can provide a readily accessible indirect indicator of patient health status for both health services and epidemiologic research purposes. Copyright \u00a9 2002 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.682","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T23:25:36Z","timestamp":1030317936000},"page":"149-157","source":"Crossref","is-referenced-by-count":44,"title":["Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients"],"prefix":"10.1002","volume":"11","author":[{"given":"Olivia","family":"Leoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Michielotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Calandrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Zangaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Riboldazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Oria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Lecchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmario","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,3,20]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Handbook of Parkinson's Disease","author":"Koller WC","year":"1992"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199712040-00006"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130209"},{"key":"e_1_2_1_5_2","first-page":"146","article-title":"Parkinson's disease: update on pharmacologic options to slow progression and treat symptoms","volume":"27","author":"Ahlskog JE","year":"1992","journal-title":"Hosp Formul"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199915020-00004"},{"key":"e_1_2_1_7_2","first-page":"21","article-title":"Treatment of Parkinson's disease by cell transplantation","volume":"16","author":"Cesaro P","year":"2001","journal-title":"Funct Neurol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3_Suppl_3.S1"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(199803\/04)7:2<131::AID-PDS337>3.0.CO;2-I"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90016-G"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90106-6"},{"key":"e_1_2_1_12_2","first-page":"212","article-title":"Medications and their monitoring in Parkinson's disease in Dunedin","volume":"105","author":"Caradoc\u2010Davies TH","year":"1992","journal-title":"NZ Med J"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000113494"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1168"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008669826178"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.3.181"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_1_18_2","volume-title":"Guidelines for ATC Classification","author":"Anonymous","year":"1993"},{"key":"e_1_2_1_19_2","volume-title":"International Classification of Diseases","author":"Anonymous","year":"1997"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1991.tb04711.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)00254-7"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1995.tb00465.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(00)00040-7"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199417003-00003"},{"issue":"1","key":"e_1_2_1_25_2","first-page":"S179","article-title":"Medical treatment of levodopa\u2010induced dyskinesias","volume":"47","author":"Rascol O","year":"2000","journal-title":"Ann Neurol"},{"issue":"4","key":"e_1_2_1_26_2","first-page":"40","article-title":"Workshop IV: Drug treatment guidelines for the long\u2010term management of Parkinson's disease","volume":"247","author":"Reichmann H","year":"2000","journal-title":"J Neurol"},{"key":"e_1_2_1_27_2","unstructured":"Neurol Sci 2000 21 Suppl. LIMPE\u2014Lega Italiana per la lotta contro la malattia di Parknson le sindromi extrapiramidali e le demenze. Linee Guida per il Trattamento della Malattia di Parkinson 2000"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(00)00045-6"},{"issue":"1","key":"e_1_2_1_29_2","first-page":"433","article-title":"Variability in patterns of drug usage","volume":"46","author":"Leufkens HG","year":"1994","journal-title":"J Pharm Pharmacol"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00228-0"},{"key":"e_1_2_1_31_2","first-page":"1","article-title":"Geriatric drug use and adverse event reporting in 1990","volume":"12","author":"Burke LB","year":"1992","journal-title":"Annu Rev Gerontol Geriatr"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908033210507"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.23.6.839"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.6.1173"},{"key":"e_1_2_1_35_2","first-page":"45","article-title":"Comorbidit\u00e9s neurologiques du parkinsonisme","volume":"157","author":"Bodenman P","year":"2001","journal-title":"Rev Neurol"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410160303"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.149.4.443"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-6846-2_15"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(00)00039-0"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.5.595"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.67.4.492"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1159\/000116692"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(00)00010-9"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.3109\/10401239709147768"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1_Suppl_1.S49"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(99)00011-5"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130606"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198812000-00004"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1997.tb04506.x"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90003-6"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(97)00168-8"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.682","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T13:05:22Z","timestamp":1700312722000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1002\/pds.682"],"URL":"https:\/\/doi.org\/10.1002\/pds.682","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}